Collection of Additional Data Followed the Study IFM 2013-04
NCT03089411 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 340
Last updated 2017-03-27
Summary
Collection of retrospective additional data (survival, biological, disease response data) following the study IFM 2013-04.
Conditions
- Myeloma Multiple
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 66 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-20
- Primary Completion
- 2017-07-15
- Completion
- 2017-07-15
Countries
- France
Study Locations
More Related Trials
-
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT00337506 ·Status: TERMINATED ·Phase: PHASE2
-
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
NCT01134484 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
NCT00573391 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
NCT00531453 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
NCT01464112 ·Status: COMPLETED ·Phase: PHASE1
-
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
NCT03896737 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
NCT01554852 ·Status: UNKNOWN ·Phase: PHASE3
-
VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma
NCT00391157 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT00438841 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
NCT03217812 ·Status: COMPLETED ·Phase: PHASE3
-
GEM05 for Patients With Multiple Myeloma Under 65 Years
NCT00461747 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
NCT00560352 ·Status: TERMINATED ·Phase: PHASE1
-
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
NCT03402295 ·Status: COMPLETED ·Phase: PHASE3
-
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
NCT02145715 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
NCT01916252 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
NCT01045681 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
NCT00908232 ·Status: COMPLETED ·Phase: PHASE2
-
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00124579 ·Status: TERMINATED ·Phase: PHASE2
-
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
NCT00256776 ·Status: TERMINATED ·Phase: PHASE3
-
Study of VTD in Waldenstrom's Macroglobulinemia
NCT03335098 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
NCT00063726 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
NCT02541383 ·Status: COMPLETED ·Phase: PHASE3
-
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
NCT01114048 ·Status: UNKNOWN ·Phase: PHASE2
-
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
NCT01063179 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT03234972 ·Status: COMPLETED ·Phase: PHASE3